Healthcare

Rep. Louie Gohmert: ‘I Will Use Zinc, Erythromycin, and Hydroxychloroquine’ to Fight Coronavirus

Published

3 years ago

July 30, 2020

“My doctor and I are all in,” Rep. Louie Gohmert, R-Texas, told “Hannity” Wednesday while on quarantine from having contacted coronavirus. “And I got a text just before I came on from a dear friend, [a] doctor, who just found out he had it, and he said he started a HCQ [hydroxychloroquine] regimen, too.”

“So zinc, erythromycin, and hydroxychloroquine,” Gohmert added, “and that will start just in the next day or two.”

Gohmert explained that he found out he had coronavirus only when he was tested when he got invited to join President Trump on a trip to West Texas. “He [Trump] called me from Air Force One on the way home tonight and I said … ‘Mr. President, if you would not [have] invited me to go with you to West Texas, I would never have known I had the coronavirus,'” Gohmert said. “That’s what I got tested for it and then I found out I had it.”

Watch full interview with Sean Hannity on Fox News.

Related Topics:coronavirus hydroxychloroquine Louie Gohmert Texas

China

FDA will work with China to import cancer drugs due to U.S. shortages

Published

2 days ago

June 7, 2023

Sara Carter Staff

Earlier this week the United States Food and Drug Administration (FDA) announced it will be working to import chemotherapy drugs from, of all places, China. The drug, called Cisplatin, is to help “ramp up supply amidst rampant drug shortages in the U.S.” reports Foreign Desk News.

Foreign Desk News writes:

Cisplatin comes from drugmaker Qilu Pharmaceutical, which is marketed and produced in China but has not been approved by the FDA. According to a May 24 letter, Qilu will work with the Canadian-based drug company Apotex to import and distribute the medication, which will come in 50-milligram vials with Chinese labels.

“The FDA is responding to yet another generic drug shortage,” said Edmund F. Haislmaier, an expert in healthcare policy and markets at The Heritage Foundation. “The underlying cause of those shortages is that generic drugs have become low-margin commodity products,” he added.

Last week on Twitter, FDA commissioner Dr. Robert Califf said the partnership with Qilu Pharmaceutical is temporary but will provide patients with a potentially life-extending drug.

“The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages,” Califf said.

The public should rest assured that we will continue all efforts within our authority to help the industry that manufactures and distributes these drugs meet all patient needs for the oncology drugs impacted by shortages. https://t.co/8XvOuJzSL4

— Dr. Robert M. Califf (@DrCaliff_FDA) June 3, 2023

Foreign Desk News adds:

The latest move by the FDA is sure to spark concern and debate in Congress, as lawmakers in the House and Senate have called on the Biden administration to de-couple the U.S. economy from the Chinese markets, given Beijing’s aggressive push to expand in the South-China Sea and eventually take over the island state of Taiwan. China has also spread illegal and dangerous synthetic opioids and fentanyl drugs across the U.S. southern border, resulting in the devastating deaths of many Americans.